(Q30867908)

27 June 2017

1 reference

title

Newer atypical antipsychotic medication versus clozapine for schizophrenia (English)

1 reference

27 June 2017

0 references

A Tuunainen

1

1 reference

PubMed ID

10796559

27 June 2017

K Wahlbeck

series ordinal

2

1 reference

PubMed ID

10796559

27 June 2017

S M Gilbody

series ordinal

3

1 reference

27 June 2017

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

1 reference

27 June 2017

2

1 reference

27 June 2017

CD000966

1 reference

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

27 June 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Absence of evidence is not evidence of absence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Trials to assess equivalence: the importance of rigorous methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Myocarditis and cardiomyopathy associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

New antipsychotic medications: strategies for evaluation and selected findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Two cases of olanzapine-induced reversible neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

Clozapine versus typical neuroleptic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000966

10.1002/14651858.CD000966

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference

PubMed ID

10796559